182 related articles for article (PubMed ID: 15147435)
1. Rituximab as treatment for refractory kidney transplant rejection.
Becker YT; Becker BN; Pirsch JD; Sollinger HW
Am J Transplant; 2004 Jun; 4(6):996-1001. PubMed ID: 15147435
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Impact of rituximab therapy for treatment of acute humoral rejection.
Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
5. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
6. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
[TBL] [Abstract][Full Text] [Related]
8. Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: A nationwide cohort study.
Perrottet N; Fernández-Ruiz M; Binet I; Dickenmann M; Dahdal S; Hadaya K; Müller T; Schaub S; Koller M; Rotman S; Moll S; Hopfer H; Venetz JP; Aubert V; Bühler L; Steiger J; Manuel O; Pascual M; Golshayan D;
PLoS One; 2021; 16(4):e0250829. PubMed ID: 33930037
[TBL] [Abstract][Full Text] [Related]
9. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
[TBL] [Abstract][Full Text] [Related]
10. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab.
Lehnhardt A; Mengel M; Pape L; Ehrich JH; Offner G; Strehlau J
Am J Transplant; 2006 Apr; 6(4):847-51. PubMed ID: 16539643
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in highly sensitized kidney transplant recipients.
Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
[TBL] [Abstract][Full Text] [Related]
12. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation.
Vianna RM; Mangus RS; Fridell JA; Weigman S; Kazimi M; Tector J
Transplantation; 2008 May; 85(9):1290-3. PubMed ID: 18475186
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
Han S; Hwang E; Park S; Park U; Kim H; Cho W
Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
[TBL] [Abstract][Full Text] [Related]
14. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
15. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab.
Baran DA; Lubitz S; Alvi S; Fallon JT; Kaplan S; Galin I; Correa R; Courtney MC; Chan M; Spielvogel D; Lansman SL; Gass AL
Transplant Proc; 2004 Dec; 36(10):3164-6. PubMed ID: 15686719
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
[TBL] [Abstract][Full Text] [Related]
17. Administration of Antithymocyte Globulin (Rabbit) to Treat a Severe, Mixed Rejection Episode in a Pregnant Renal Transplant Recipient.
Kutzler HL; Ye X; Rochon C; Martin ST
Pharmacotherapy; 2016 Apr; 36(4):e18-22. PubMed ID: 26892892
[TBL] [Abstract][Full Text] [Related]
18. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
[TBL] [Abstract][Full Text] [Related]
19. Treatment of humoral rejection with rituximab.
Garrett HE; Groshart K; Duvall-Seaman D; Combs D; Suggs R
Ann Thorac Surg; 2002 Oct; 74(4):1240-2. PubMed ID: 12400781
[TBL] [Abstract][Full Text] [Related]
20. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
